In this report, the Structural Heart Devices Market has been segmented by Product, Type, Component, End Use, and Geography.

Structural Heart Devices Market, Segmentation by Product

The Structural Heart Devices Market has been segmented by Product into Heart Valve Devices - Transcatheter Heart Valves and Surgical Heart Valves.

Transcatheter Heart Valves

Transcatheter heart valves account for approximately 60% of the structural heart devices market. These devices are widely adopted due to their minimally invasive nature and ability to treat high-risk patients with valvular diseases. Increasing demand for transcatheter aortic valve replacement (TAVR) procedures and advances in device technology contribute significantly to market growth.

Surgical Heart Valves

Surgical heart valves represent around 40% of the market, catering to patients requiring traditional open-heart surgery for valve replacement. Their proven durability and long-term clinical outcomes make them a reliable choice in treating complex valvular conditions. Innovations in tissue engineering and design improvements continue to enhance their market appeal.

Structural Heart Devices Market, Segmentation by Type

The Structural Heart Devices Market has been segmented by Type into Surgical Aortic Valve Replacement, Transcatheter Aortic Valve Replacement, Mitral Repair, and Left Atrial Appendage Closure

Surgical Aortic Valve Replacement

Surgical aortic valve replacement (SAVR) accounts for approximately 35% of the structural heart devices market. This open-heart procedure remains the gold standard for treating aortic valve disease, particularly in patients who are younger and considered low risk. Its durability and long-term clinical success continue to sustain strong demand.

Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR) holds a significant share of around 45% of the market. TAVR’s minimally invasive approach offers an alternative to open surgery, making it a preferred option for elderly and high-risk patients. Rapid technological advancements and a growing body of clinical evidence support its expanding adoption.

Mitral Repair

Mitral repair represents about 15% of the structural heart devices market, focusing on restoring the function of the mitral valve. This segment includes both minimally invasive procedures and traditional surgery, with emphasis on treating mitral regurgitation. Continued innovation in repair techniques and device designs is driving growth.

Left Atrial Appendage Closure

Left atrial appendage closure (LAAC) comprises approximately 5% of the market. This minimally invasive procedure reduces the risk of stroke in patients with atrial fibrillation who cannot take long-term anticoagulation. Increased focus on stroke prevention and advances in device technology are boosting LAAC adoption.

Structural Heart Devices Market, Segmentation by Component

The Structural Heart Devices Market has been segmented by Component into Replacement Procedures - TAVR Procedures & Savr Procedures, Repair Procedures - Closure Procedures, Annuloplasty, Valvuloplasty and TMVR Procedures.

TAVR Procedures

Transcatheter aortic valve replacement (TAVR) procedures account for approximately 55% of the replacement procedures segment. This minimally invasive approach is widely preferred for high-risk patients with aortic valve stenosis. The growing adoption of catheter-based interventions and advancements in valve technology are key factors driving TAVR market growth.

SAVR Procedures

Surgical aortic valve replacement (SAVR) holds about 30% of the replacement procedures segment. This traditional open-heart surgery method remains a vital option for patients unsuitable for transcatheter procedures. The proven long-term durability and established clinical outcomes of SAVR support its continued use, especially in younger and lower-risk patients.

Closure Procedures

Closure procedures represent around 20% of the repair procedures segment. These interventions, including septal defect closures and left atrial appendage closures, are crucial for preventing stroke and improving cardiac function. Increased emphasis on minimally invasive options and technological advancements contribute to their rising adoption.

Annuloplasty

Annuloplasty holds a 15% share within repair procedures, focusing on repairing the valve annulus to restore valve competency. This technique is particularly beneficial in cases of mitral and tricuspid valve regurgitation, offering durable results with minimal complications. Advancements in device design and surgical techniques are driving growth in this segment.

Valvuloplasty

Valvuloplasty procedures contribute approximately 10% to the repair segment, primarily used to treat valve stenosis in high-risk patients. This balloon-based intervention temporarily improves valve function and is often used as a bridge to more definitive treatments. The rise in elderly populations with comorbidities supports market expansion.

TMVR Procedures

Transcatheter mitral valve replacement (TMVR) is an emerging segment with a market share of around 5% in the repair category. TMVR provides a minimally invasive solution for patients with severe mitral regurgitation who are unsuitable for surgery. Ongoing clinical trials and technological innovation are expected to drive future adoption.

Structural Heart Devices Market, Segmentation by End Use

The Structural Heart Devices Market has been segmented by End Use into Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Labs, and Others

Hospitals

Hospitals account for approximately 60% of the structural heart devices market. These facilities handle a high volume of complex cardiac procedures, including both surgical and transcatheter interventions. The presence of advanced medical infrastructure and experienced cardiac surgeons ensures the extensive use of structural heart devices.

Ambulatory Surgical Centers

Ambulatory surgical centers contribute about 20% of the market share. These centers focus on minimally invasive cardiac procedures and offer cost-effective alternatives to hospital-based surgeries. Their growth is supported by the increasing popularity of same-day discharge procedures and emphasis on patient convenience.

Cardiac Catheterization Labs

Cardiac catheterization labs represent approximately 15% of the market. These labs play a pivotal role in performing transcatheter interventions like TAVR and mitral valve repair. The adoption of advanced imaging technologies and the rising demand for minimally invasive procedures are driving growth in this segment.

Others

The 'Others' category, which includes specialty clinics and diagnostic centers, makes up around 5% of the market. These facilities increasingly use structural heart devices to enhance diagnostic accuracy and expand treatment capabilities. Growth in this segment is supported by efforts to broaden access to cardiac care.

Structural Heart Devices Market, Segmentation by Geography

In this report, the Structural Heart Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Structural Heart Devices Market Share (%), by Geographical Region

North America

North America leads the structural heart devices market, holding approximately 40% of the global share in 2024. The region benefits from a strong presence of advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and continuous investment in innovative device technologies. Leading market players and favorable reimbursement policies also drive growth.

Europe

Europe contributes around 30% to the global market share, driven by rising demand for minimally invasive procedures and a growing elderly population. The region’s focus on early diagnosis and preventive healthcare supports the widespread adoption of structural heart devices. Collaborative research efforts and regulatory support further enhance market expansion.

Asia Pacific

Asia Pacific is experiencing rapid growth, accounting for approximately 20% of the market share. The region’s expansion is fueled by increasing healthcare investments, improving medical infrastructure, and a rising burden of cardiovascular conditions. Countries like China and India are at the forefront, supported by favorable government policies and rising patient awareness.

Middle East and Africa

The Middle East and Africa contribute about 6% to the global market. Growth in this region is supported by government-led healthcare modernization initiatives and increasing focus on improving cardiac care. The growing availability of advanced medical equipment and rising demand for minimally invasive cardiac procedures are key drivers.

Latin America

Latin America represents nearly 4% of the structural heart devices market. Countries like Brazil and Mexico are leading adoption, supported by expanding healthcare access and rising investments in cardiovascular treatment options. Continued focus on public health programs and technological advancements is expected to drive further growth.

This report provides an in depth analysis of various factors that impact the dynamics of Global Structural Heart Devices Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• High prevalence of heart diseases
• Rapidly aging global population

• Rising congenital heart defect cases - The increasing prevalence of congenital heart defects (CHDs) is a major driver of the structural heart devices market. CHDs represent one of the most common types of birth defects globally, requiring early detection and timely medical intervention. As diagnostic capabilities improve and awareness increases, more patients are being identified at an early stage, necessitating a range of interventional solutions such as septal occluders, valve repair devices, and closure systems to manage these structural abnormalities.

  Technological advancements and the growing adoption of minimally invasive procedures have significantly enhanced treatment outcomes for patients with CHDs. With healthcare providers emphasizing early intervention and lifelong cardiac care, the demand for innovative and durable structural heart devices continues to rise. This trend is further reinforced by pediatric and adult congenital heart programs globally, contributing to consistent market growth across diverse healthcare settings.

Restraints

• Shortage of skilled healthcare personnel
• Existing technological limitations

• Lengthy regulatory approval times - Lengthy regulatory approval processes pose a significant restraint to the growth of the structural heart devices market. Devices such as transcatheter heart valves, occluders, and annuloplasty systems must undergo extensive clinical testing and scrutiny to meet stringent safety and efficacy standards set by regulatory bodies like the FDA and EMA. This prolonged evaluation period delays the time-to-market for new technologies, making it harder for manufacturers to respond quickly to emerging patient needs or innovations.

  For smaller firms and startups, these regulatory delays often result in increased development costs and resource burdens, which can limit product innovation and competitiveness. Even for larger players, uncertainties in the approval timeline hinder strategic planning and revenue forecasting. As the demand for advanced and minimally invasive cardiac devices grows, the industry's ability to accelerate access to life-saving technologies is constrained by the current pace of regulatory clearance, slowing overall market momentum.

Opportunities

• Expansion across emerging markets
• Supportive government healthcare initiatives
• Increasing patient awareness levels - The growing levels of patient awareness about cardiovascular health and available treatment options are opening new opportunities for the structural heart devices market. Patients are becoming more informed about the symptoms, risks, and long-term consequences of structural heart diseases, leading to earlier consultations and proactive healthcare decisions. This heightened awareness drives demand for timely diagnosis and access to advanced interventional therapies, such as transcatheter valve replacements and septal defect closures.

  Increased exposure to medical information through digital health platforms, telemedicine services, and public health campaigns empowers patients to explore less invasive treatment alternatives with improved outcomes and shorter recovery times. This behavioral shift significantly benefits manufacturers of minimally invasive structural heart devices, as patients now actively seek modern procedures that align with their preferences for safety and comfort. As a result, healthcare systems are witnessing a growing acceptance and adoption of these devices in both elective and urgent care settings.

  Furthermore, the rise in health literacy and patient advocacy has prompted healthcare providers to emphasize shared decision-making and individualized care. This environment fosters innovation, where device developers are encouraged to design patient-friendly solutions with enhanced usability, durability, and compatibility. The convergence of awareness, access to information, and proactive care behavior is expected to accelerate the structural heart device market’s expansion in both developed and emerging economies.

Key players in Global Structural Heart Devices Market include:

• Boston Scientific Corporation
• Medtronic
• Edwards Lifesciences Corporation
• Abbott Laboratories
• ST. JUDE MEDICAL
• Biomerics
• Comed BV
• LivaNova PLC
• JenaValve Technology, Inc.
• CardioKinetix

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis